Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer
- 20 Downloads
A subcutaneous (SC) formulation of trastuzumab, a potent humanized anti-Human Epidermal growth factor Receptor 2 (HER2) receptor monoclonal antibody, with a recombinant hyaluronidase (Herceptin Hylecta™; Herceptin®) is indicated in the USA and EU for the treatment of HER2-positive breast cancer. In the phase III pivotal HannaH trial, SC trastuzumab was noninferior to the standard intravenous (IV) formulation of trastuzumab with respect to trough drug concentrations and pathological complete response in patients with HER2-positive early breast cancer. Other clinical outcomes, including event-free survival and overall survival rates, were generally similar between the formulation groups. SC trastuzumab had a manageable tolerability profile in patients with HER2-positive early or metastatic breast cancer, with the safety profile being generally similar to that of the IV formulation. In the phase III PrefHER and MetaspHER trials, more patients preferred SC over IV trastuzumab and more healthcare professionals expressed satisfaction with the SC formulation. Relative to IV trastuzumab, SC trastuzumab offers a quicker and more convenient dosage regimen, thereby potentially improving patient convenience, providing economic benefit and optimizing the use of medical resources. Thus, given the high preference for SC trastuzumab and its generally similar efficacy and tolerability profile to that of the IV formulation, SC trastuzumab is the preferred treatment of choice in patients receiving trastuzumab for the treatment of HER2-positive early or metastatic breast cancer.
During the peer review process, the manufacturer of SC trastuzumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Young-A Heo and Yahiya Syed are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
- 6.National Comprehensive Cancer Network. NCCN guidelines: breast cancer. 2019. http://nccn.org. Accessed 15 Oct 2019.
- 7.Genentech Inc. Herceptin™ (trastuzumab injection, powder, lyophilized, for solution): US Prescribing Information. 2019. http://www.fda.gov/. Accessed 15 Oct 2019.
- 8.European Medicines Agency. Herceptin 150 mg powder for infusion and 600 mg solution for injection in vial: summary of product characteristics. 2019. http://www.ema.europa.eu/. Accessed 15 Oct 2019.
- 9.Genentech Inc. Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk injection, for subcutaneous use): US Prescribing Information. 2019. https://www.fda.gov/. Accessed 15 Oct 2019.
- 11.Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–78.CrossRefGoogle Scholar
- 12.Jackisch C, Hegg R, Stroyakovskiy D, et al. HannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. Eur J Cancer. 2016;62:62–75.CrossRefGoogle Scholar
- 13.Jackisch C, Stroyakovskiy D, Pivot X, et al. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomized clinical trial. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2019.0339.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Cicin I, Oukkal M, Mahfouf H, et al. An open-label, multinational, phase IIIb study to evaluate patient and satisfaction, safety and efficacy of subcutaneous administration of trastuzumab in patients with HER2-positive early breast cancer (ML28851) in adjuvant/neo-adjuvant setting [abstract no. 363 (PB-158)]. Eur J Cancer. 2018;92(Suppl 3):S102–3.CrossRefGoogle Scholar
- 16.Ludtke-Heckenkamp K, Kummel S, Ruf-Dordelmann A, et al. Second interim analysis of HerSCin, a German non-interventional study of subcutaneous trastuzumab for HER2-positive early breast cancer in routine clinical practice [abstract no. 178P]. Ann Oncol. 2017;28(Suppl 5):53–4.Google Scholar
- 17.Gligorov J, Ataseven B, Verrill M, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHER phase III study’s primary analysis of 2573 patients. Eur J Cancer. 2017;82:237–46.CrossRefGoogle Scholar
- 18.Kummel S, Tondini CA, Abraham J, et al. Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis [abstract no. 323P]. Ann Oncol. 2018;29(Suppl 8):viii103.Google Scholar
- 22.Valachis A, Carlsson L, Sundqvist M, et al. Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden [abstract no. P6-17-24]. Cancer Res. 2019;79(4 Suppl).Google Scholar
- 23.Jacquin JPP, Uwer L, Savignoni A, et al. Safety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: the French HERMIONE non-interventional prospective study [abstract no. 220P]. Ann Oncol. 2018;29(Suppl 8):viii70-1.Google Scholar
- 24.Syrios J, Pappa E, Volakakis N, et al. Real-world data on health-related quality of life assessment in patients with breast cancer receiving subcutaneous trastuzumab. Breast Cancer. 2018;12:1–10.Google Scholar
- 25.European Medicines Agency. Herceptin: CHMP assessment report. 2013. http://www.ema.europa.eu/. Accessed 29 Aug 2019.
- 26.Pivot X, Gligorov J, Muller V, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHER study. Ann Oncol. 2014;25(10):1979–87.CrossRefGoogle Scholar
- 30.Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018. http://www.fda.gov/. Accessed 23 Jul 2019.
- 31.European Medicines Agency. Draft guideline on the role of the pathological complete response as an endpoint in neoadjuvant breast cancer studies. 2014. http://www.ema.europa.eu/. Accessed 23 Jul 2019.
- 42.Quartino AL, Hillenbach C, Li J, et al. Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer. Cancer Chemother Pharmacol. 2016;77(1):77–88.CrossRefGoogle Scholar